News
NBRVF
0.0002
NaN%
--
Weekly Report: what happened at NBRVF last week (0212-0216)?
Weekly Report · 1d ago
Weekly Report: what happened at NBRVF last week (0205-0209)?
Weekly Report · 02/12 10:20
Weekly Report: what happened at NBRVF last week (0129-0202)?
Weekly Report · 02/05 10:25
Weekly Report: what happened at NBRVF last week (0122-0126)?
Weekly Report · 01/29 10:18
Weekly Report: what happened at NBRVF last week (0115-0119)?
Weekly Report · 01/22 10:21
Weekly Report: what happened at NBRVF last week (0108-0112)?
Weekly Report · 01/15 10:18
Weekly Report: what happened at NBRVF last week (0101-0105)?
Weekly Report · 01/08 10:21
Weekly Report: what happened at NBRVF last week (1225-1229)?
Weekly Report · 01/01 10:18
Weekly Report: what happened at NBRVF last week (1218-1222)?
Weekly Report · 12/25/2023 10:25
Weekly Report: what happened at NBRVF last week (1211-1215)?
Weekly Report · 12/18/2023 10:28
Weekly Report: what happened at NBRVF last week (1204-1208)?
Weekly Report · 12/11/2023 10:25
Weekly Report: what happened at NBRVF last week (1127-1201)?
Weekly Report · 12/04/2023 10:24
Weekly Report: what happened at NBRVF last week (1120-1124)?
Weekly Report · 11/27/2023 10:21
Weekly Report: what happened at NBRVF last week (1113-1117)?
Weekly Report · 11/20/2023 10:20
Weekly Report: what happened at NBRVF last week (1106-1110)?
Weekly Report · 11/13/2023 10:15
Weekly Report: what happened at NBRVF last week (1030-1103)?
Weekly Report · 11/06/2023 10:18
Weekly Report: what happened at NBRVF last week (1023-1027)?
Weekly Report · 10/30/2023 10:28
Weekly Report: what happened at NBRVF last week (1016-1020)?
Weekly Report · 10/23/2023 10:22
Weekly Report: what happened at NBRVF last week (1009-1013)?
Weekly Report · 10/16/2023 10:19
Weekly Report: what happened at NBRVF last week (1002-1006)?
Weekly Report · 10/09/2023 10:23
More
Webull provides a variety of real-time NBRVF stock news. You can receive the latest news about Nabriva Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About NBRVF
Nabriva Therapeutics PLC is a biopharmaceutical company. The Company is engaged in the commercialization, research and development of novel anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.